In this study, we want to learn more about the experiences and activities of high school-aged youth after a neurological event. This study will also help us to understand the perspectives of youth and a parent/caregiver through photos and stories.

Have you been diagnosed with Low Risk Breast Cancer? Have you already been treated with surgery? If so, you may be able to take part in a research study looking at the effect of regional nodal radiotherapy.

If you or your child had or currently have abnormal cell growth or a related condition, including brain and nervous system tumors, you may be able to take part in a research study. This is a study for patients who are receiving treatment at UNC hospitals. In this study, we will collect samples to better understand the causes of your disease.

Pancreatic cancer has one of the lowest survival rates for all cancers, but there are some people who achieve long-term survival. We are looking at those patients, with the goal of identifying what are some treatments and experiences that do work. Learning about treatment combinations and unique therapies that have led to success can open doors for where our research should be focused moving forward.

Do you have small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC)? Has your lung cancer come back or did not get better with the last treatment you were given? If so, you may be able to take part in a gene therapy research study that uses your own modified immune cells as treatment.

The purpose of this study is to find out if treatment with the study drug, Bexmarilimab, along with standard of care can help with your type of cancer.

This is a prospective study that will look for the kinetics of circulating tumor DNA (ctDNA) in patients with hematologic and pediatric cancer before and after undergoing standard of care treatment regimens where radiation therapy is a treatment.

The purpose of this study is to determine if MIRV plus Bev can help to prevent your cancer from returning or delaying your cancer's return.

Have you been diagnosed with relapsed or refractory multiple myeloma? If so, you may be able to take part in a research study looking at the safety of giving a new drug to patients with multiple myeloma.

Have you been diagnosed with triple negative breast cancer? If so, you may be able to take part in a research study looking at the safety of giving a new drug called Sacituzumab Govitecan with or without a drug called Pembrolizumab to patients with PDL-1-negative metastatic triple negative breast cancer.